Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
4.607
-0.173 (-3.63%)
Oct 26, 2026, 11:10 AM EDT - Market open
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $27.78M in the quarter ending June 30, 2026, with 2,778.55% growth. This brings the company's total for the last twelve months to $31.52M, up 893.01% year-over-year. In the year 2025, Aligos Therapeutics had annual revenue of $2.19M, down -44.59%. That makes Aligos Therapeutics the 31,060th largest company in the world by revenue and 4,100th in the United States.
Revenue (ttm)
$31.52M
Revenue Growth
+893.01%
P/S Ratio
0.95
Revenue / Employee
$384,366
Employees
82
Market Cap
28.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.19M | -1.76M | -44.59% |
| Dec 31, 2024 | 3.95M | -11.58M | -74.60% |
| Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
| Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
| Dec 31, 2021 | 4.36M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Celularity | 18.67M |
| Metagenomi Therapeutics | 13.56M |
| Evaxion | 7.49M |
| ABVC BioPharma | 797.92K |
| Impact BioMedical | 35.00K |
ALGS News
- 20 days ago - Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 weeks ago - Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Aligos Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38) - TheFly